Oncimmune Holdings PLC Result of General Meeting (5353C)
January 22 2018 - 6:21AM
UK Regulatory
TIDMONC
RNS Number : 5353C
Oncimmune Holdings PLC
22 January 2018
22 January 2018
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Result of General Meeting
Nottingham, UK - 22 January 2018: Oncimmune Holdings plc (AIM:
ONC.L), Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) liquid biopsy platform technology, announces that at
the Company's General Meeting held earlier today, all resolutions
were duly passed.
The General Meeting was called to consider resolutions to grant
authorities from shareholders to allot the ordinary shares pursuant
to the subscription for new ordinary shares by Genostics Company
Limited as announced by the Company on 2 January 2018.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Giles Balleny, Hugh Kingsmill Moore
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Berenberg (Joint Broker)
Toby Flaux, Charlotte Sutcliffe
+44 (0)20 3207 7800
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT(R) platform
technology. Oncimmune has pioneered the development of autoantibody
tests that can detect cancer up to four years earlier than other
methods and can be applied to a very wide range of solid tumour
types. The Company's first product, EarlyCDT(R)-Lung, was launched
in 2012, as a CLIA test in the USA and since then over 150,000
commercial tests have been sold. EarlyCDT(R)-Lung is available
through physicians in the US and also privately in the UK and other
regions. EarlyCDT(R)-Lung is being used in the largest ever
randomised trial for the early detection of lung cancer using
biomarkers, the National Health Service (NHS) Scotland ECLS study
of 12,210 high-risk smokers. EarlyCDT(R) tests for liver and
ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with
testing facilities in the US, joined AIM in May 2016 under the
ticker ONC.L. For more information, visit www.oncimmune.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMFLLFLVFFLBBB
(END) Dow Jones Newswires
January 22, 2018 06:21 ET (11:21 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024